Show simple item record

dc.contributor.authorAuner, Holger W
dc.contributor.authorGavriatopoulou, Maria
dc.contributor.authorDelimpasi, Sosana
dc.contributor.authorSimonova, Maryana
dc.contributor.authorSpicka, Ivan
dc.contributor.authorPour, Ludek
dc.contributor.authorDimopoulos, Meletios A
dc.contributor.authorKriachok, Iryna
dc.contributor.authorPylypenko, Halyna
dc.contributor.authorLeleu, Xavier
dc.contributor.authorDoronin, Vadim
dc.contributor.authorUsenko, Ganna
dc.contributor.authorHajek, Roman
dc.contributor.authorBenjamin, Reuben
dc.contributor.authorDolai, Tuphan Kanti
dc.contributor.authorSinha, Dinesh Kumar
dc.contributor.authorVenner, Christopher P
dc.contributor.authorGarg, Mamta
dc.contributor.authorStevens, Don Ambrose
dc.contributor.authorQuach, Hang
dc.contributor.authorJagannath, Sundar
dc.contributor.authorMoreau, Phillipe
dc.contributor.authorLevy, Moshe
dc.contributor.authorBadros, Ashraf
dc.contributor.authorAnderson, Larry D
dc.contributor.authorBahlis, Nizar J
dc.contributor.authorFacon, Thierry
dc.contributor.authorMateos, Maria Victoria
dc.contributor.authorCavo, Michele
dc.contributor.authorChai, Yi
dc.contributor.authorArazy, Melina
dc.contributor.authorShah, Jatin
dc.contributor.authorShacham, Sharon
dc.contributor.authorKauffman, Michael G
dc.contributor.authorRichardson, Paul G
dc.contributor.authorGrosicki, Sebastian
dc.date.accessioned2021-04-28T15:37:53Z
dc.date.available2021-04-28T15:37:53Z
dc.date.issued2021-03-23
dc.identifier.urihttp://hdl.handle.net/10713/15536
dc.description.abstractElderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial. Post hoc analyses were performed to compare XVd versus Vd safety and efficacy according to age and frailty status (<65 and ≥65 years, nonfrail and frail). Patients ≥65 years with XVd had higher ORR (OR 1.77, p =.024), ≥VGPR (OR, 1.68, p =.027), PFS (HR 0.55, p =.002), and improved OS (HR 0.63, p =.030), compared with Vd. In frail patients, XVd was associated with a trend towards better PFS (HR 0.69, p =.08) and OS (HR 0.62, p =.062). Significant improvements were also observed in patients <65 (ORR and TTNT) and nonfrail patients (PFS, ORR, ≥VGPR, and TTNT). Patients treated with XVd had a lower incidence of grade ≥ 2 peripheral neuropathy in ≥65 year-old (22% vs. 37%; p =.0060) and frail patients (15% vs. 44%; p =.0002). Grade ≥3 TEAEs were not observed more often in older compared to younger patients, nor in frail compared to nonfrail patients. XVd is safe and effective in patients <65 and ≥65 and in nonfrail and frail patients with previously treated MM. © 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.en_US
dc.description.urihttps://doi.org/10.1002/ajh.26172en_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofAmerican Journal of Hematologyen_US
dc.subjectmultiple myelomaen_US
dc.subjectfrailtyen_US
dc.subjectbortezomiden_US
dc.subjectclinical trialen_US
dc.subjectselinexoren_US
dc.subjectexportinen_US
dc.subjectkaryopherinsen_US
dc.titleEffect of Age and Frailty on the Efficacy and Tolerability of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Previously Treated Multiple Myelomaen_US
dc.typeArticleen_US
dc.identifier.doi10.1002/ajh.26172
dc.identifier.pmid33755235
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record